Spectrum Pharmaceuticals (NASDAQ: SPPI) today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE